Maxigen Biotech Inc (1783) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Maxigen Biotech Inc (1783) has a cash flow conversion efficiency ratio of 0.049x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (NT$79.84 Million ≈ $2.52 Million USD) by net assets (NT$1.63 Billion ≈ $51.25 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See 1783 defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Maxigen Biotech Inc - Cash Flow Conversion Efficiency Trend (2009–2025)
This chart illustrates how Maxigen Biotech Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Maxigen Biotech Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Maxigen Biotech Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Bajaj Healthcare Limited
NSE:BAJAJHCARE
|
0.094x |
|
Amica S.A.
WAR:AMC
|
0.059x |
|
Icon Group
TA:ICON
|
-0.040x |
|
Dong Yang Pipe
KO:008970
|
-0.111x |
|
Nicola Mining Inc
V:NIM
|
0.542x |
|
Companhia Estadual de Distribuição de Energia Elétrica
SA:CEED3
|
-0.016x |
|
Idsud S.A
PA:ALIDS
|
-0.907x |
|
Coya Therapeutics, Inc. Common Stock
NASDAQ:COYA
|
-0.127x |
Annual Cash Flow Conversion Efficiency for Maxigen Biotech Inc (2009–2025)
The table below shows the annual cash flow conversion efficiency of Maxigen Biotech Inc from 2009 to 2025. For the full company profile with market capitalisation and key ratios, see how much is Maxigen Biotech Inc worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | NT$1.54 Billion ≈ $48.44 Million |
NT$290.22 Million ≈ $9.14 Million |
0.189x | -12.97% |
| 2024-12-31 | NT$1.38 Billion ≈ $43.32 Million |
NT$298.22 Million ≈ $9.40 Million |
0.217x | +72.42% |
| 2023-12-31 | NT$1.36 Billion ≈ $42.88 Million |
NT$171.20 Million ≈ $5.39 Million |
0.126x | -39.27% |
| 2022-12-31 | NT$1.30 Billion ≈ $40.82 Million |
NT$268.34 Million ≈ $8.45 Million |
0.207x | +101.08% |
| 2021-12-31 | NT$1.14 Billion ≈ $35.97 Million |
NT$117.59 Million ≈ $3.70 Million |
0.103x | +19.10% |
| 2020-12-31 | NT$860.23 Million ≈ $27.10 Million |
NT$74.39 Million ≈ $2.34 Million |
0.086x | -22.02% |
| 2019-12-31 | NT$851.32 Million ≈ $26.82 Million |
NT$94.42 Million ≈ $2.97 Million |
0.111x | -45.19% |
| 2018-12-31 | NT$842.98 Million ≈ $26.56 Million |
NT$170.58 Million ≈ $5.37 Million |
0.202x | +291.31% |
| 2017-12-31 | NT$796.25 Million ≈ $25.09 Million |
NT$41.18 Million ≈ $1.30 Million |
0.052x | +16.39% |
| 2016-12-31 | NT$781.38 Million ≈ $24.62 Million |
NT$34.72 Million ≈ $1.09 Million |
0.044x | +133.57% |
| 2015-12-31 | NT$829.86 Million ≈ $26.14 Million |
NT$-109.85 Million ≈ $-3.46 Million |
-0.132x | -703.35% |
| 2014-12-31 | NT$877.01 Million ≈ $27.63 Million |
NT$-14.45 Million ≈ $-455.29K |
-0.016x | +34.46% |
| 2013-12-31 | NT$888.39 Million ≈ $27.99 Million |
NT$-22.34 Million ≈ $-703.71K |
-0.025x | -155.33% |
| 2012-12-31 | NT$385.66 Million ≈ $12.15 Million |
NT$17.53 Million ≈ $552.17K |
0.045x | +121.89% |
| 2011-12-31 | NT$369.25 Million ≈ $11.63 Million |
NT$-76.64 Million ≈ $-2.41 Million |
-0.208x | -389.53% |
| 2010-12-31 | NT$395.39 Million ≈ $12.46 Million |
NT$-16.76 Million ≈ $-528.16K |
-0.042x | -168.87% |
| 2009-12-31 | NT$313.03 Million ≈ $9.86 Million |
NT$19.27 Million ≈ $607.14K |
0.062x | -- |
About Maxigen Biotech Inc
Maxigen Biotech Inc. researches, develops, produces, and sells implantable medical devices in Taiwan, America, Europe, rest of Asia, and internationally. It operates through two segments, Biomedical Products and Consumer Products. The company provides biomedical materials, such as collagen and bone supplements; beauty and skincare products; and medical devices for ophthalmology, otolaryngology, d… Read more